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introduction: Postoperative nausea and vomiting (PONV) is a displeasing experience 
that distresses surgical patients during the first 24  h after a surgical procedure. The 
incidence of postoperative nausea occurs in about 50%, the incidence of postoperative 
vomiting is about 30%, and in high-risk patients, the PONV rate could be as high as 80%. 
Therefore, the study design of this single arm, non-randomized, pilot study assessed the 
efficacy and safety profile of a triple therapy combination with palonosetron, dexameth-
asone, and promethazine to prevent PONV in patients undergoing craniotomies under 
general anesthesia.
Methods: The research protocol was approved by the institutional review board and 
40 subjects were provided written informed consent. At induction of anesthesia, a triple 
therapy of palonosetron 0.075  mg IV, dexamethasone 10  mg IV, and promethazine 
25  mg IV was given as PONV prophylaxis. After surgery, subjects were transferred 
to the surgical intensive care unit or post anesthesia care unit as clinically indicated. 
Ondansetron 4 mg IV was administered as primary rescue medication to subjects with 
PONV symptoms. PONV was assessed and collected every 24 h for 5 days via direct 
interview and/or medical charts review.
results: The overall incidence of PONV during the first 24 h after surgery was 30% 
(n = 12). The incidence of nausea and emesis 24 h after surgery was 30% (n = 12) and 
7.5% (n = 3), respectively. The mean time to first emetic episode, first rescue, and first 
significant nausea was 31.3 (±33.6), 15.1 (±25.8), and 21.1 (±25.4) hours, respectively. 
The overall incidence of nausea and vomiting after 24–120 h period after surgery was 
February 2016 | Volume 3 | Article 12
Bergese et al. Palonosetron: PONV Prophylaxis Effect – Craniotomy
Frontiers in Medicine | www.frontiersin.org
inTrODUCTiOn
Postoperative nausea and vomiting (PONV) is a displeasing 
experience that distresses surgical patients during the first 24 h 
after a surgical procedure (1–8). The incidence of postoperative 
nausea in general population occurs in about 50%, the incidence 
of postoperative vomiting is about 30%, and in high-risk patients, 
the PONV rate could be as high as 80% (2, 3, 5, 6, 8–10). In addi-
tion, the literature reports a PONV incidence after craniotomy of 
43–70% (10, 11). PONV could be a moderate-to-severe postop-
erative problem that increases the chances of developing several 
complications, including suture dehiscence, bronchopulmonary 
aspiration, elevated intraocular and intracranial pressures, delay 
recovery and discharge time, etc. (2, 4, 7, 9, 12).
According to the Consensus Guidelines for the Management 
of Postoperative Nausea and Vomiting, a combination of 
antiemetic medications is recommended as the most appropri-
ate regimen for patients with moderate and high-risk factors for 
PONV (6). Early PONV are those episodes that occur in a 0–2 h 
timeframe, while delayed PONV occurs during the 2–24 h period 
(6). Postdischarge nausea and vomiting (PDNV) are episodes 
that occur after the patient has left the hospital (6). PONV is a 
complex occurrence that can be triggered by numerous receptor 
pathways [dopamine type 2, serotonin type 3 (5-HT3), histamine 
type 1, muscarinic cholinergic type 1, and neurokinin type 1]; 
therefore, we have several alternatives to prevent and treat PONV 
(2, 3, 5, 6, 8).
The Apfel Simplified Risk Score is one of the two most com-
monly used and effective risk scores to assess inpatient risk of 
developing PONV when undergoing inhaled anesthesia. The 
Apfel Simplified Risk Score is based on four predictors: female 
gender, non-smoking status, history of PONV and/or motion 
sickness, and use of postoperative opioids. The incidence of 
PONV with the presence of 0, 1, 2, 3, and 4 risk factors increases 
drastically, by 10, 20, 40, 60, and 80%, respectively. Patients with 
0–1 are considered low risk, those patients with 2 risk factors fall 
into “medium risk”; and those patients with 3 or more risk factors 
are considered to be “high risk” (6).
Literature describes dexamethasone as an effective drug to 
prevent PONV (6–8, 13). These data show it to be an inexpensive 
and excellent antiemetic prophylactic agent commonly used 
worldwide, especially if it is administrated early before surgery 
(6–8, 13). Its mechanism of action remains undetermined; most 
likely, its peripherally prostaglandin antagonism, serotonergic 
antagonism, and endorphin releasing properties play important 
roles in PONV management. It has a long biological half-life of 
36–48 h and excellent side-effects profile after a single dose of 8 mg 
intravenous (IV) given before anesthesia induction. However, 
the literature reported cases with awake patients experiencing 
perineal burning, itching, and tingling after receiving a dose of 
dexamethasone 8 mg IV for PONV prophylaxis (14).
Promethazine is a phenothiazine derivative that competitively 
blocks histamine [H(1)] receptors and exhibits antiemetic and 
sedative properties. IV infusion of promethazine typically 
relieves PONV after 5 min and lasts for 2–6 h (7, 15). However, in 
ambulatory surgical settings, promethazine has shown concern-
ing sedative effects (7, 8, 15).
Palonosetron is the latest serotonin receptor antagonist (3, 
6–8, 13, 16, 17). Serotonin is an ubiquitous central and peripheral 
neurotransmitter thought to be the predominant mediator of the 
perception of nausea and triggering of the vomiting response (18). 
This occurs in both the brain and the periphery via the serotonin 
5-hydroxytryptamine type 3 [5-HT(3)] receptor pathways (19). 
Palonosetron, compared to older 5-HT3 receptor antagonist, 
such as ondansetron, granisetron, dolasetron, and ramosetron, 
has higher receptor binding affinity and longer plasma half-life 
(40 h) (3, 6–8, 13, 16, 17). The most effective dose for PONV is 
a single 0.075  mg IV dose administered over 10  s right before 
anesthesia induction (5, 6, 12, 13). The most common side effects 
of palonosetron described in the literature are electrocardiogram 
QT prolongation, bradycardia, headache, and constipation (18, 
20). The US Food and Drug Administration (FDA) approved its 
use for prevention of PONV in March 2008 (7, 20). Palonosetron 
is a fairly new 5-HT3 receptor antagonist, and studies have shown 
controversial results concerning QTc prolongation (5, 16).
QTc prolongation may suggest an inherited predisposition to 
sudden cardiac death. It may also uncover an increased vulner-
ability to the development of life threatening ventricular tachy-
cardia in patients being considered for treatment with a known 
QT-prolonging drug (21–24). The American Heart Association/
30% (n = 12). The percentage of subjects without emesis episodes over 24–120 h post-
operatively was 70% (n = 28). No subjects presented a prolonged QTc interval ≥500 ms 
before and/or after surgery.
Conclusion: Our data demonstrated that this triple therapy regimen may be an ade-
quate alternative regimen for the treatment of PONV in patients undergoing neurological 
surgery under general anesthesia. More studies with a control group should be per-
formed to demonstrate the efficacy of this regimen and that palonosetron is a low risk 
for QTc prolongation.
ClinicalTrials.gov identifier: NCT02635828 (https://clinicaltrials.gov/show/
NCT02635828).
Keywords: nausea, vomiting, emesis, postoperative complications, QTc
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FiGUrE 1 | Patient screening flowchart.
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American College of Cardiology Foundation (AHA/ACCF) 
describes a QTc of >470 ms for males and >480 ms for females 
as prolonged, with a QTc value >500  ms considered highly 
abnormal for both genders (22, 23, 25). Consequently, the litera-
ture shows data with direct relationship between palonosetron 
administration and QTc prolongation (26). Nonetheless, other 
studies have shown palonosetron to have none to mild effects on 
the QTc interval (5, 16).
Therefore, the study design of this single arm, non- randomized, 
pilot study assessed the efficacy and safety profile of a triple 
therapy combination with palonosetron, dexamethasone, and 
promethazine to prevent PONV in patients undergoing crani-
otomies under general anesthesia.
METHODS
The research protocol was approved by the institutional review 
board and 40 subjects provided written informed consent prior 
to any research procedures at The Ohio State University Wexner 
Medical Center and completed the study. The protocol was not 
registered in clinicaltrial.gov during enrollment period because it 
was not part of our institutional standard operation procedures; 
thus, it was registered after enrollment completion (ClinicalTrials.
gov Identifier: NCT02635828). The study’s inclusion criteria 
consisted of adult patients, 18–85 years, undergoing neurological 
surgery (opening of the cranium and dura mater) requiring at 
least 1 h of general anesthesia and at least 72 h of postoperative 
hospitalization. These subjects were assessed preoperatively using 
the Apfel Simplified Risk Score. Exclusion criteria consisted of 
subject with prisoner or mentally ill status, history of alcohol or 
drug abuse, hypersensitivity to any of the medications admin-
istered in the protocol, female subjects who are pregnant or 
breastfeeding, history of vomiting or severe nausea 24  h prior 
to a procedure, history of treatment with any drug or treatment 
within last 24 h prior to start of the treatment, and/or subjects 
who have participated in any other clinical study.
An electrocardiogram (ECG) was obtained at baseline, 24 and 
120 h after surgery, if the subject remained hospitalized. At induc-
tion of anesthesia, a triple therapy of palonosetron 0.075 mg IV, 
dexamethasone 10 mg IV, and promethazine 25 mg IV was given 
as PONV prophylaxis.
The general anesthesia regimen recommended began with 
premedication of midazolam 1–2 mg IV promptly before the sub-
ject was transferred to the operating room. Propofol 1–2 mg/kg 
IV and fentanyl 0.75–1.5 μg/kg IV were used to induce anesthesia. 
Rocuronium 0.6–1.2 mg/kg−1 was administered before tracheal 
intubation. General anesthesia was preserved with volatile 
anesthetics (sevoflurane, desflurane, or isoflurane) and clinical 
judgment regulated titration concentrations. The analgesia dur-
ing anesthesia maintenance was done with Fentanyl boluses of 
0.5–2.0 μg/kg−1 IV and/or hydromorphone boluses 0.5 mg IV. In 
order to reverse the residual neuromuscular block at the end of 
the procedure, neostigmine and glycopyrrolate were used.
After surgery, subjects were transferred to the surgical intensive 
care unit (SICU) or post anesthesia care unit (PACU) as clinically 
indicated. Ondansetron 4 mg IV was administered as primary res-
cue medication to subjects with PONV symptoms. Subjects who 
did not respond to this initial treatment were given a second line of 
therapy. PONV was assessed and collected every 24 h for 5 days via 
direct interview and/or medical charts review. Episodes of nausea, 
vomiting, and administration of rescue therapy for either nausea 
or vomiting were recorded, in addition to the severity of each nau-
seous or emetic episode. Nausea was rated by the patients utilizing 
a verbal response scale (0–10), with 0 being no nausea at all and 10 
being severe nausea. Vomiting was evaluated by the investigator or 
nursing staff numerically as either 0 (no vomiting), 1 (mild vomit-
ing), 2 (moderate vomiting), or 3 (severe vomiting). Following the 
first 24 h after administration of the prophylactic triple therapy, 
an ECG was conducted and standard of care blood was drawn for 
safety analysis. If the patient was discharged before the 5-day time 
period, the patient was then contacted via phone call by research 
personnel to complete PONV and safety assessments.
Descriptive statistics are reported as mean ± SE and median 
(range) or total number and percentage. Binomial test were 
performed to compare the Apfel risk factors between our study 
and literature. These data were analyzed using Statistical Analysis 
Software, version 9.3 (SAS Institute Inc., Cary, NC, USA). 
Significance was accepted if p ≤ 0.05.
rESUlTS
A total of 54 subjects were enrolled and screened for entry into 
the study. Of the 54 subjects who were screened, 14 were screen 
failures and 40 subjects were eligible to complete the study 
through 120 h follow-up. The primary reasons for screen failure 
were failure to meet all the inclusion/exclusion criteria (n = 5), 
consent withdrawal (n = 0), and others (n = 9) (Figure 1). No 
side effects associated with study medications showed significant 
differences. The subject’s demographics, surgical variables, and 
Apfel risk factors are listed in Table 1.
The overall incidence of PONV during the first 24 h after sur-
gery was 30% (n = 12). The incidence of nausea and emesis 24 h 
after surgery was 30% (n = 12) and 7.5% (n = 3), respectively. Of 
those patients who experienced nausea during the first 24 h after 
surgery, the median worst nausea score was 6 (8, 10). The median 
severity of vomiting was 2 (1, 3), corresponding to moderate 
severity. Rescue medication during the first 24 h was used on 12 
patients (30%) (Table 2).
TaBlE 3 | intent to treat population.
Time to treatment failure, mean (SD) Palonosetron
Number of subjects 40
Time to first emetic episode 31.3 (33.6)
Time to first rescue 15.1 (25.8)
Time to first significant nausea 21.1 (25.4)
TaBlE 2 | Postoperative nausea and vomiting outcome variables in the 
first 24 h.
POnV outcome variables Palonosetron
Number of subjects 40
PONV, n (%) 12 (30%)
Vomiting, n (%) 3 (7.5%)
Worst vomiting score, median (IQR) 2 (1, 3)
Any nausea incidence, n (%) 12 (30%)
Significant Nausea incidence (a score ≥4 on the VRS), n (%) 11 (27.5%)
Worst nausea score, median (IQR) 6 (8, 10)
Rescue antiemetics, n (%) 12 (30%)
Postoperative opioid consumption, median (IQR), oral 
morphine, mg
68.5 (36, 140)
VRS = verbal rating scale, IQR = interquartile range.
TaBlE 1 | Patient demographics and surgical variables.
Demographics and surgical variables Palonosetron
Number of subjects 40
Age, mean (SD), years 50.6 (16.7)
Weight, mean (SD), kg 84.0 (18.4)
Height, mean (SD), cm 170.4 (9.8)
BMI, mean (SD) 28.8 (5.8)
Race-White, n (%) 39 (97)
ASA I/II/III 0/8/32
Female, n (%) 21 (52)
History of PONV and/or motion of sickness n (%) 6 (15)
Non-smoker status, n (%) 32 (80)
Postoperative opioids, n (%) 40 (100)
Apfel risk factors, n (%)
1 (low risk) 2 (5%)
2 (moderate risk) 21 (52.5%)
3 or 4 (high risk) 17 (42.5%)
Duration of anesthesia, mean (SD), h 4.5 (2.0)
Duration of SICU stay, mean (SD), h 54.9 (43.5)
Duration of total hospital stay, mean (SD), h 66.2 (45.3)
IQR, interquartile range.
February 2016 | Volume 3 | Article 14
Bergese et al. Palonosetron: PONV Prophylaxis Effect – Craniotomy
Frontiers in Medicine | www.frontiersin.org
The mean time to first emetic episode, first rescue, and first 
significant nausea was 31.3 (±33.6), 15.1 (±25.8), and 21.1 
(±25.4) hours, respectively (Table 3).
In the course of the early PONV (0–2  h), the incidence of 
PONV was 10% (n = 4), nausea and vomiting occurred in 10% 
(n = 4) and 0% (n = 0), respectively. The worst nausea and vomit-
ing score was 9 (8, 10) and 3 (3, 3), respectively (Table 4).
The overall incidence of nausea and vomiting after 24–120 h 
period after surgery was 30% (n = 12). The percentage of subjects 
without emesis episodes over 24–120 h postoperatively was 70% 
(n  =  28). Of those subjects who experienced nausea during 
24–120 h after surgery, the median severity was 6 (6.0, 10). The 
median severity of vomiting was 2.5 (2, 3), corresponding to 
moderate severity (Table 4).
No subjects presented a prolonged QTc interval ≥500  ms 
before and/or after surgery. The percentage of subjects who 
presented a prolonged QTc interval ≥450 ms at baseline and 24 h 
after surgery were 22.5% (n = 9) and 13.9% (n = 5), respectively. 
The incidence of a change in QTc interval larger than 60 ms 24 h 
after surgery was 2.8% (n = 1). The incidence of prolonged QTc 
interval ≥450  ms 120  h post-surgery was 19.2% (n =  5). The 
percentage of subjects who presented a change in QTc interval 
larger than 30 and 60 ms were 11.5% (n = 3) and 0%, respectively 
(Table 5).
DiSCUSSiOn
This study successfully demonstrates that triple therapy with 
palonosetron, dexamethasone, and promethazine for prevention 
of postoperative nausea and vomiting in patients undergoing neu-
rological surgery and general anesthesia is an adequate alternative. 
It has been established that the uncomfortable effects of vomiting 
on intracranial pressure can lead to permanent and catastrophic 
consequences on patients undergoing craniotomy (10).
A PONV incidence of 40–80% is predicted by the Apfel scale 
in patients with medium to high risk (6). Nonetheless, our study 
reported a PONV incidence of 24–46% (Table 6) having statisti-
cal significance results in subjects with four risk factors with a 
PONV incidence of 25% compared with 80% described by Gan 
et al. (6). These facts support our hypothesis that triple therapy 
with palonosetron, dexamethasone, and promethazine does 
indeed reduce the incidence of PONV in subjects undergoing 
craniotomy and can be used as an alternative regimen.
The most common side effects that could be associated with 
palonosetron described in clinical trials are ECG QT prolonga-
tion (5%), bradycardia (4%), headache (3%), and constipation 
(2%) (20). The results from our study showed only a 2.8% of 
ECG QT prolongation >60 ms and none of the subjects had ECG 
QT prolongation >500 ms. The rest of common side effects were 
challenging to assess in neurosurgical settings.
In our study, only 13.9% of patients presented a prolonged QTc 
interval of ≥450 ms and 0% of patients presented a prolonged 
QTc interval ≥500 ms. Since prolongation of QTc interval was not 
our primary objective, more studies with a proper power analysis 
should be performed to conclude that palonosetron is a low risk 
for QTc prolongation.
Latz et  al. presented a prospective study that evaluated the 
incidence and risk factors of PONV in 229 patients undergoing 
craniotomy (10). It found a PONV incidence in 47% of patients 
(10). In our study, palonosetron was demonstrated to be an 
effective antiemetic on the triple therapy by reducing the PONV 
incidence to 30%.
Chun et al. published a randomized, double-blind, placebo-
controlled trial that proved the efficacy of palonosetron as PONV 
prophylaxis in 204 patients (27). In this study, the palonosetron 
group presented 33% incidence of PONV compared to 47% of the 
TaBlE 4 | Postoperative nausea and vomiting outcome variables in the first 24 h.
Outcome variables 0–2 h
Palonosetron
24–48 h
Palonosetron
24–72 h
Palonosetron
24–96 h
Palonosetron
24–120 h
Palonosetron
Number of subjects 40 40 40 40 40
PONV, n (%) 4 (10) 9 (22.5) 11 (27.5) 12 (30) 12 (30)
Vomiting, n (%) 0 2 (5) 4 (10) 5 (12.5) 6 (15)
Worst vomiting score, median (IQR) 3 (3, 3) 3 (3, 3) 2.5 (1.5, 3) 2 (2, 3) 2 (2, 3)
Any nausea incidence, n (%) 4 (10) 9 (22.5) 19 (47.5) 25 (62.5) 27 (67.5)
Significant nausea incidence (a score ≥4 on the VRS), n (%) 4 (10) 8 (20) 17 (42.5) 23 (57.5) 25 (62.5)
Worst nausea score, median (IQR) 9 (8, 10) 7 (6, 10) 6 (5, 10) 6 (6, 10) 6 (6, 10)
Rescue antiemetics, n (%) 4 (10) 2 (5) 2 (5) 2 (5) 2 (5)
Postoperative opioid consumption, median (IQR), oral 
morphine milligram
NA 45 (27, 117.5) 45 (27, 98.7) 45 (30, 91) 45 (30, 90)
VRS = verbal rating scale; IQR = interquartile range.
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placebo group on a 0–24 h postoperative period (27). In addition, 
the PONV incidence in the 0–72 h period was 33% for palono-
setron compared to 53% for the placebo group (27). Our study 
showed a 30% PONV incidence that shows a strong correlation 
with this study.
Mansour designed a double-blind, active controlled study 
with 150 patients comparing the use of dexamethasone alone, 
dexamethasone–metoclopramide therapy, or dexamethasone–
palonosetron combination therapy (28). The dexamethasone–
palonosetron combination therapy proved to be the most effective 
by significantly reducing the PONV incidence 12–24  h after 
surgery compared with dexamethasone and dexamethasone–
metoclopramide therapies (16 vs. 48 vs. 40%, respectively) (28).
Min et al. presented a retrospective study that analyzed a database 
of 81 patients who underwent general anesthesia. The main focus 
of this study was to evaluate changes in QTc interval throughout 
different time points in surgery (incision, 30, 60, 90, and 120 min 
after incision). The results demonstrated that the incidence of 
QTc prolongation ≥500 ms was higher in patients who received 
0.075 mg of palonosetron intravenously than those who did not 
during general anesthesia (26). Nonetheless, this study had several 
limitations, including not being a randomized prospective study 
(26). Therefore, factors that could have affected the QTc interval 
were not controlled (26). On the other hand, in our study, there 
were no clinically important changes in the baseline, 24 h period 
and discharge ECG, and no shifts of clinical concerns noted.
A study by Morganroth et  al. included 221 healthy subjects 
who were assigned to receive one of the following five treatments: 
placebo, palonosetron (0.25, 0.75, or 2.25 mg), or moxifloxacin 
(400 mg) in order to study the effects of palonosetron on QTc 
interval (29). All three doses of palonosetron showed no sig-
nificant effects on QTc prolongation (29). The main objective of 
the study was developed in accordance with the International 
Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) E14 in 
order to analyze the potential of cardiovascular toxicity (29). No 
significant QTc prolongations were detected (29). This supports 
our results for QTc prolongation.
Our study also presented certain limitations that should be 
mentioned. To begin with, this study enrolled 40 subjects who 
received study medication and completed all the assessments, but 
the study was designed without a control group; therefore, we 
were not able to compare the results from this regimen. In addi-
tion, headache, constipation, fatigue, and dizziness are the most 
common side effects of palonosetron; however, both side effects 
are also expected postoperative symptoms after craniotomies (18).
COnClUSiOn
The primary objective of this study was to evaluate the efficacy 
of triple therapy with palonosetron, dexamethasone, and pro-
methazine for the prevention of PONV in subjects undergoing 
craniotomies. Our results showed a PONV incidence of 30% and 
an accumulative incidence of nausea and vomiting of 3 (7.5%). In 
addition, our data had shown the incidence of a change in QTc 
interval larger than 60 ms 24 h after surgery was 2.8% (n = 1). 
In conclusion, this study had demonstrated that the prophylactic 
regimen used could be an adequate regimen to prevent PONV 
in subjects undergoing craniotomies under general anesthesia. 
However, since prolongation of QTc interval was not our primary 
objective, and we did not have a control group; more studies 
with a proper power analysis and combined therapy should be 
TaBlE 5 | QTc variables.
Baseline N 
(40)
PO 24 h N 
(36)
PO 120 h N 
(26)
Prolonged QTc interval >500 ms 0 (0%) 0 (0%) 0 (0%)
Prolonged QTc interval >450 ms 9 (22.5%) 5 (13.9%) 5 (19.2%)
δQTc interval >30 ms NA 1 (2.8%) 3 (11.5%)
δQTc interval >60 ms NA 1 (2.8%) 0 (0%)
TaBlE 6 | apfel comparison in POnV 24 h: literature vs. our findings.
apfel 
risk 
factor
N = 40 POnV 24 h 
incidence
risk for POnV 
(apfel) (%)
p-Value Difference Ci
1 2 0 (0.0%) 20 NA NA
2 21 5 (23.9%) 40 0.132 (0.05, 0.42)
3 13 6 (46.2%) 60 0.309 (0.19, 0.73)
4 4 1 (25%) 80 0.006 (−0.17, 0.67)
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performed to demonstrate the efficacy of this regimen and that 
palonosetron is a low risk for QTc prolongation.
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